Contract facts
FederalNo full NAICS 325412 intel page yet. Browse NAICS intelligence
OSELTAMIVIR PHOSPHATE (TAMIFLU) 30MG AND 75MG CAPSULES is a federal award for Aspr/Orm-Sns held by Genentech Usa, Inc. Estimated value $45.1M ($45.1M obligated). Current period of performance ends Jan 29, 2027. Last award drew 1 bidder. Place of performance: SOUTH SAN FRANCISCO, CA.
OSELTAMIVIR PHOSPHATE (TAMIFLU) 30MG AND 75MG CAPSULES
Recompete timing
PublicCurrent PoP ends Jan 29, 2027 (162 days remaining). Agencies typically plan 12–18 months ahead — at 5.3 months out, that window is already open. The buying decision is likely already in motion.
Incumbent footprint
Public recordGenentech Usa, Inc — $136.1M obligated across 34 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 75A50325F80003?
75A50325F80003 (Tamiflu and) is a Aspr/Orm-Sns award with an estimated value of $45.1M, currently held by Genentech Usa, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
Which office awarded 75A50325F80003?
Aspr/Orm-Sns awarded 75A50325F80003 to Genentech Usa, Inc.
Who is the incumbent on 75A50325F80003?
Genentech Usa, Inc is the incumbent with $136.1M across 34 related awards in SCOUT’s public footprint. The current period of performance ends Jan 29, 2027.
When does Genentech Usa, Inc’s 75A50325F80003 come up for recompete?
SCOUT tracks a period-of-performance end of Jan 29, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.